Olema Pharmaceuticals/$OLMA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Olema Pharmaceuticals

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Ticker

$OLMA
Sector
Primary listing

Employees

117

OLMA Metrics

BasicAdvanced
$759M
-
-$1.94
1.93
-

What the Analysts think about OLMA

Analyst ratings (Buy, Hold, Sell) for Olema Pharmaceuticals stock.

Bulls say / Bears say

Olema ended Q2 2025 with $361.9 million in cash, cash equivalents, and marketable securities, providing enough runway to fund late-stage trials for more than a year (GlobeNewswire)
In Q2 2025, Olema secured FDA agreement on a 90 mg once-daily dose of palazestrant for both the OPERA-01 and OPERA-02 Phase 3 trials, streamlining study design and supporting faster enrollment (GlobeNewswire)
On September 2, 2025, Olema entered a clinical trial agreement with Pfizer to test palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer, expanding its partnership network and combination therapy prospects (Investing.com)
Olema’s net loss widened to $43.8 million in Q2 2025 from $30.4 million a year earlier, driven by a one-time $10 million milestone payment and higher R&D expenses, increasing near-term cash burn (GlobeNewswire)
Although Olema held $361.9 million in cash, cash equivalents, and marketable securities, its cash position fell by $30.8 million quarter over quarter, pointing to significant spending and possible funding risks if clinical progress slows (GlobeNewswire)
Top-line results from the OPERA-01 Phase 3 trial of palazestrant are not expected until the second half of 2026, leaving a catalyst gap that could put pressure on the share price in the meantime (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

OLMA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

OLMA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $OLMA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs